Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 127Colonic Neoplasms 71Rectal Neoplasms 56Neoplasm Metastasis 22Pancreatic Neoplasms 21Stomach Neoplasms 16Precursor Cell Lymphoblastic Leukemia-Lymphoma 14Leukemia 11Carcinoma, Hepatocellular 11Neoplasms 10Lymphoma 10Burkitt Lymphoma 8Adenocarcinoma Of Esophagus 8Cholangiocarcinoma 6Adenocarcinoma 6Parkinson Disease 4, Autosomal Dominant Lewy Body 5Esophageal Neoplasms 5Leukemia, Biphenotypic, Acute 4Intestinal Neoplasms 4Gastrointestinal Neoplasms 4Esophageal Squamous Cell Carcinoma 4Digestive System Neoplasms 4Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 3Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 3Lymphoma, Non-Hodgkin 3Lymphoma, Large B-Cell, Diffuse 3Gallbladder Neoplasms 3Biliary Tract Neoplasms 3Rectal Diseases 2Neurotoxicity Syndromes 2

Interventions

xaliproden 2Polyamines 1Oxaliplatin 1Leucovorin 1Fluorouracil 12,2'-dithiodiethanesulfonic acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Paresthesia × Leucovorin × Clear all
NCT00305188 2016-05-04

Evaluation of the Efficacy of Xaliproden (SR57746A) in Preventing the Neurotoxicity of Oxaliplatin / 5FU/LV Chemotherapy.

Sanofi

Phase 3 Completed
879 enrolled
Gastrointestinal

Neoplasm Metastasis, Paresthesia, Colorectal Neoplasms, Neurotoxicity Syndromes

Data powered by HemOnc (CC BY 4.0) Colophon âš¡